amilial Mediterranean Fever (FMF) is an autosomal recessive systemic autoinflammatory disease with recurrent serositis episodes often accompanied with fever. [1] [2] [3] [4] We postulate to underline a rare clinical form of FMF which manifests itself with prolonged hip pain. Herein, we report a patient with protracted hip arthritis who had an early response to infliximab therapy.
CASE REPORT
Twenty-seven year old male patient applied to the outpatient clinic for pain in buttocks and both legs. He said that the pain existed for a few months and progressed during that time. During the physical examination the straight leg raise test was 50 degree positive on the right. C-reactive protein (CRP) in the laboratory tests was 1.52 mg/dl (normal range 0.015-0.50 mg/dl). Except from the high level of CRP, there were no positive laboratory findings. The family history for rheumatic diseases was negative. The lumbar, chest radiograph and urinalysis were normal. Anti-inflammatory drug was prescribed and the patient was called for control exami- nation. At the follow-up he had pain in his left hip. His pain had inflammatory features. Bilateral range of motion in hip joint, especially the internal and external rotation, was limited in physical examination. The sacroiliac joint (SIJ) examination tests were bilateral positive. The hip radiography showed flattening of the bilateral femoral head and acetabular subchondral cysts ( Figure 1 ). CRP levels were 7.9 mg/dl and proteinuria (1+) was present in the urinalysis. After learning more about the history of the patient it was revealed that he had an appendectomy. He didn't describe oral or genital aphthae, uveitis, genital discharge, skin rash, previously occurrence of joint pain and swelling, weight loss, night sweating, chest or abdominal pain, fever, dry eyes. A first-degree consanguineous marriage between his mother and father was present. The bilateral hip magnetic resonance imaging (MRI) was consistent with chronic sequelae of arthritis ( Figure 2 
DISCUSSION
FMF may present in various clinical situations. Diagnosis is based on clinical features. The most common complaints are recurrent abdominal pain and fever episodes. 2 Abdominal pain may be misdiagnosed as acute abdomen. Diagnosis of 30-40% of the patients is skipped and appendectomy is carried out, as it was the case with our patient. 5 Arthritis is often found in FMF. Although arthritis is commonly seen together with attacks, it can sometimes be the first finding of FMF. The typical involvement is monoarthritis in the lower extremity joints, which is not migratory and doesn't cause sequela. Although very rare it can proceed with chronic arthritis or sacroiliitis and cause damage to hip joint. 6 Chronic hip joint involvement is characterized with repetetive or prolonged attacks. Limitation of range of motion in the joint is very common, but the degree of functional impairment is variable. Changes in radiolu- cent appearance suggesting avascular necrosis in the form of subchondral eggshell have been reported. This appearance was also present in the direct radiography of our patient. 7, 8 FMF can also be associated with other diseases causing hip involvement. In the ten case series published by Younes et al. (hip involvement was shown radiologically in all patients), four patients showed isolated FMF, four patients ankylosing spondylitis (AS), one patient possible AS and one patient juvenile idiopathic arthritis (JIA), accompanied by FMF. 9 Cattan et al. reported cases of FMF together with chronical inflammatory bowel disease. 10 We excluded other inflammatory diseases that could occur together with FMF in our patient. The most important therapeutic agent for the disease is colchicine. It brings full remission in 65% and partial remission in 30% of the patients. [11] [12] [13] However, there are cases in literature with progressive chronic hip involvement which do not respond to colchicine treatment and warrant biological agents. Daysal et al. described a twenty-one year old woman with chronic hip involvement, not responsive to colchicine and NSAIDs. Other disease modifying anti-rheumatoid drugs (DMARDs) were prescribed but clinical response was not attained. Then the patient was started on intravenous infliximab treatment. Four-five days after the infliximab treatment, the sedimentation and CRP values of the patient returned to normal. This case supports the role of TNF alpha in pathogenesis. In some reports TNF treatment was found to be ineffective.
14 Since our patient had no response to colchicine, NSAIDs and DMARDs, we started an anti-TNF (infliximab) treatment. Improvement of the clinical condition and the laboratory values was observed after the first dose.
In conclusion, Familial Mediterranean Fever should be kept in mind in patients with chronic hip arthritis. Significant results may be obtained with biological drugs (such as anti-TNF) in the treatment of these patients. 
